Search Results - therapeutic+substance

249 Results

Sort By:

A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 3/13/2025 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

Gut-specific serotonin transporter inhibitors for treatment of constipation

Value Proposition· Potent inhibition of serotonin transporter (SERT) in GI system· Luminally and or/peripherally-restricted SERT inhibitors· Result in enhanced action of serotonin in stimulation of GI motility· Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...

Published: 3/13/2025 | Inventor(s): Pankaj Pasricha, James Barrow, Qian Li, Pablo de Leon, Yifang Huang

Keywords(s): Antagonists/Inhibitors, Biomarker, Disease Indication, Gastrointestinal Disorders, Mechanism-of-action Biomarker, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology

Novel Oxazolidinones for Treatment of Bacterial Infections

Marketing Summary DraftNovel Oxazolidinones for Treatment of Bacterial InfectionsJHU Ref #: C14633Value Proposition· Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy· Positive activity demonstrated against M. tuberculosis· MIC values the same or better than the current antibiotics in the...

Published: 3/13/2025 | Inventor(s): Gyanu Lamichhane, J. Ippoliti

Keywords(s): Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors

Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...

Published: 3/14/2025 | Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas

Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules

Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection

Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...

Published: 3/13/2025 | Inventor(s): Norman Haughey, Barbara Slusher, Camilo Rojas

Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > HIV

Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases

Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Adoptive Proinflammatory Myeloid Cell Therapy for Cancer

Unmet Need: Prostate cancer is one of the most commonly diagnosed cancers in the male population; roughly one out of ten men will be diagnosed at some point in their lives. Despite extending survival, androgen depravation therapy invariably leads to the development of lethal castration resistant prostate cancer. Similarly, pancreatic ductal carcinoma...

Published: 3/14/2025 | Inventor(s): Alan Friedman

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Whole cell

Category(s): Technology Classifications > Therapeutic Modalities > Cell Therapies, Clinical and Disease Specializations > Oncology

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 3/14/2025 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

SYNGAP antisense oligonucleotide as therapy for human cognitive disorders

Unmet Need: Recent human genetic studies have suggested that mutations in the SYNGAP1 gene are linked to intellectual disability (ID), autism spectrum disorders (ASD), neurodevelopmental disorders, high rates of epilepsy, and schizophrenia. SYNGAP1 is a gene that encodes SynGAP, a GTPase-activating protein that is highly enriched in nerve cells in the...

Published: 3/14/2025 | Inventor(s): Richard Huganir, Ingie Hong, Yoichi Araki

Keywords(s): Biologics, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, Gene Therapy, Nucleic Acid, Single, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Psychiatry > Autism Spectrum Disorder, Clinical and Disease Specializations > Psychiatry > ADHD, Clinical and Disease Specializations > Psychiatry > Mood Disorders, Technology Classifications > Therapeutic Modalities > Gene Therapies

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 3/13/2025 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

1 2 3 4 5 6 7 8 9 10 ...